Step 1 topics → Musculoskeletal, Skin, and Connective Tissue → Gout

Gout

USMLE Step 1 trap: Reverses birefringence: gout crystals are negatively birefringent (not positive), pseudogout crystals are positively birefringent. Monosodium urate crystals (gout) are negatively birefringent and needle-shaped; CPPD crystals (pseudogout) are positively birefringent and rhomboid.

Gout is a crystal arthropathy caused by monosodium urate (MSU) deposition in joints and soft tissues, driven by hyperuricemia. On USMLE Step 1, gout shows up across multiple question formats — straightforward recall (crystal characteristics), clinical application (acute vs. chronic management decisions), and passage-based questions where a lab value or drug history is embedded to explain why a patient developed gout. The classic presentation is a middle-aged man with a red, swollen first MTP joint (podagra) waking him at night, but the exam also loves secondary gout triggers: tumor lysis syndrome, thiazide diuretics, and cyclosporine. Know why each of those causes hyperuricemia mechanistically, not just as a list.

The trickiest part of this topic isn't the facts — it's keeping the crystal analysis straight and knowing the management rules cold. Students consistently flip the birefringence: MSU crystals are needle-shaped and negatively birefringent (appear yellow when parallel to the slow axis of the compensator), while CPPD crystals in pseudogout are rhomboid and positively birefringent. That distinction is tested directly on USMLE Step 1. The management side is equally trap-heavy: allopurinol and febuxostat are urate-lowering agents, but starting them during an active flare makes things worse — rapid shifts in uric acid mobilize crystals and extend the attack.

Low-dose aspirin is another hidden trap. Students assume 'anti-inflammatory' means safe in gout, but low-dose salicylates actually reduce renal urate excretion and worsen attacks. Colchicine works by a completely different mechanism — it blocks microtubule polymerization to impair neutrophil chemotaxis, with zero effect on serum uric acid. Build your mental model around mechanism and you'll navigate the management questions without guessing.

From real student decks
86%have cards covering this topic
76%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake
Wrong: Gout crystals are positively birefringent under polarized light.
Right: Monosodium urate crystals (gout) are negatively birefringent and needle-shaped; CPPD crystals (pseudogout) are positively birefringent and rhomboid.
MSU crystals are negatively birefringent — when aligned parallel to the compensator's slow axis, they appear yellow, and blue when perpendicular. CPPD crystals are the opposite: positively birefringent, appearing blue when parallel and yellow when perpendicular. The mnemonic that helps: 'Gout is negative, like your mood when it hurts,' or just anchor it — needle = negative. If you reverse this on the exam, you'll misidentify the arthropathy and miss the whole question.
Common mistake
Wrong: Allopurinol should be started immediately during an acute gout flare to lower uric acid.
Right: Allopurinol should not be initiated during an acute flare because rapid uric acid shifts can prolong or worsen the attack; it is started after the flare resolves with bridging anti-inflammatory therapy.
Allopurinol inhibits xanthine oxidase and lowers serum uric acid over time, but any rapid shift in uric acid — up or down — can destabilize existing crystal deposits and trigger or prolong an acute attack. This is why urate-lowering therapy is always initiated after the flare fully resolves, typically with a bridging anti-inflammatory (colchicine or NSAID) for the first few months. Starting allopurinol mid-flare is a classic wrong answer on USMLE Step 1.
Common mistake
Wrong: Colchicine treats gout by lowering serum uric acid levels.
Right: Colchicine treats acute gout by inhibiting microtubule polymerization, thereby impairing neutrophil migration and phagocytosis of urate crystals, without affecting uric acid levels.
Colchicine does not touch uric acid levels — it has no effect on xanthine oxidase, urate transporters, or renal excretion. Its mechanism is purely anti-inflammatory: it binds tubulin and prevents microtubule polymerization, which blocks neutrophil migration into the joint and impairs phagocytosis of MSU crystals. The inflammatory cascade stops, the attack resolves, but serum uric acid stays exactly where it was. Urate-lowering is a separate step with a separate drug class.
Common mistake
Wrong: Low-dose aspirin is safe to use during an acute gout attack because it is anti-inflammatory.
Right: Low-dose aspirin decreases renal uric acid excretion and can precipitate or worsen gout; it should be avoided during acute attacks.
This is a dose-dependent paradox that the exam exploits. High-dose aspirin (>3g/day) is actually uricosuric — it blocks urate reabsorption. But low-dose aspirin (the cardioprotective 81mg dose) preferentially inhibits urate secretion in the proximal tubule, causing urate retention and raising serum uric acid. So a patient on baby aspirin for cardiac protection is at higher gout risk, and using it during an acute attack makes things worse. The anti-inflammatory label does not override this pharmacokinetic reality.
Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →
Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

  1. Understand the mechanisms behind urate overproduction and underexcretion — including how enzyme defects (HGPRT deficiency, PRPP synthetase overactivity), tumor lysis syndrome, and drugs like thiazides cause hyperuricemia.
  2. Distinguish gout from pseudogout using synovial fluid crystal analysis: needle-shaped, negatively birefringent MSU crystals in gout versus rhomboid, positively birefringent CPPD crystals in pseudogout.
  3. Recognize the clinical presentation of an acute gout attack — including classic podagra, nocturnal onset, warmth and erythema, common triggers (alcohol, dietary purines, dehydration, diuretics), and chronic sequelae like tophi and uric acid nephrolithiasis.
  4. Select appropriate acute flare treatment (NSAIDs, colchicine, corticosteroids) and know what to avoid — specifically why allopurinol should not be started during an active flare and why low-dose aspirin is contraindicated.
  5. Choose the right chronic urate-lowering strategy — when to use allopurinol versus febuxostat, the importance of bridging with anti-inflammatory therapy when initiating urate-lowering agents, and monitoring for drug-specific adverse effects.

Can you avoid these mistakes?

A 55-year-old man presents with acute-onset severe pain and swelling of the first MTP joint overnight. Synovial fluid shows needle-shaped crystals that appear yellow when parallel to the compensator axis. What is the crystal type, what is its birefringence, and what is the diagnosis?
A patient with a known history of gout presents with an acute flare. His primary care doctor wants to start allopurinol today to 'get ahead of the uric acid.' Why is this the wrong approach, and what is the correct management strategy for both the acute flare and transitioning to urate-lowering therapy?
A 62-year-old man on hydrochlorothiazide for hypertension develops his first gout attack. His cardiologist also has him on aspirin 81mg daily. Explain the mechanism by which each drug contributed to his hyperuricemia, and identify which one should be avoided in acute management.
You are asked to compare colchicine and allopurinol for a patient with recurrent gout. Describe the mechanism of each drug, identify which phase of gout each targets (acute vs. chronic), and explain what bridging therapy is and why it is needed when starting urate-lowering therapy.

Related topics

Bone Cells and Matrix Endochondral vs Membranous Ossification Fracture Healing Stages Compartment Syndrome

See how your Anki deck covers this topic.

Upload your deck for a free audit →